Clinical trials: Metabolism Disorder, Glucose
Diabetes Mellitus, Type 1
Reversing Type 1 Diabetes After it is Established
The primary purpose of this study is to determine if giving the combination therapy consisting of Thymoglobulin® (ATG) and Neulasta® (GCSF) to patients with established Type 1 Diabetes (T1D) is safe and secondarily, if the ATG…
- Trial name
- NCT01106157
- Testing
- Anti-Thymocyte Globin (ATG), Pegylated GCSF
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
Type 2 Diabetes
Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone
This study will compare the effect of Dapagliflozin added to Metformin vs Metformin alone on blood sugar fluctuations of adults with a recent diagnosis of Type 2 Diabetes (T2D). The duration of the protocol will be 12 weeks.
- Trial name
- MAGNNIFY (NCT04090580)
- Testing
- Continuous glucose monitoring
- Where
- Mexico
- Volunteers
- 88 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Metabolic Health, Cardio Respiratory Fitness
HIIT, Cardiorespiratory Fitness, and Metabolic Health in Healthy Young Adults
The purpose of this study was to investigate the effects of a high-intensity interval training (HIIT) intervention on cardiorespiratory fitness (CRF) and cardiometabolic health in active male university students.
- Trial name
- NCT07719296
- Testing
- High-intensity interval training (HIIT) program
- Where
- Tunisia
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- High Institute of Sports and Physical Education of Kef
Diabetes Mellitus, Type 1
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction.
- Trial name
- PRO Solo (NCT03478969)
- Testing
- Accu-Chek® Solo micropump system, mylife™ OmniPod® Insulin Management System, Multiple Daily Injections (MDI) therapy
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 181 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Efficacy and Safety of Pueraria Lobata Radix As an Adjuvant Treatment for Type 2 Diabetes Mellitus
As a dietary herb, pueraria lobata radix (PLR) has been showed to have hypoglycemic effects in animal experiments. However, there is currently a lack of evidence from randomized controlled trials.
- Trial name
- NCT06494683
- Testing
- Pueraria lobata radix
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangxi University of Traditional Chinese Medicine
Nutritional and Metabolic Diseases, Endocrine System Diseases
Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals
Categorization of glucose levels into 'healthy', 'pre-diabetic' or 'diabetic' is increasingly seen as artificial. Furthermore, most micro and macrovascular complications may be present already at the pre-diabetic stage.
- Conditions
- Nutritional and Metabolic Diseases, Endocrine System Diseases, Disorders of Environmental Origin
- Trial name
- NCT01892956
- Testing
- Nutritional intervention
- Where
- Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Diabetes Mellitus, Peripheral Neuropathies
Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep
The purpose of this study is to assess the effectiveness of pregabalin, duloxetine and amitriptyline compared with placebo in reducing pain in diabetic patients as assessed by Brief Pain Inventory (BPI).
- Trial name
- NCT00370656
- Testing
- Pregabalin, Duloxetine, Amitriptyline
- Where
- 3 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Surrey
Essential Hypertension, Type 2 Diabetes
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups…
- Conditions
- Essential Hypertension, Type 2 Diabetes, Nephropathy
- Trial name
- Hyper-Save (NCT06501651)
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Sichuan Academy of Medical Sciences
Impaired Glucose Tolerance, Diabetes
Effect of Ginseng on Glycemic Control
Ginseng (American ginseng, Asian ginseng, Korean ginseng etc) is expected to show positive hypoglycemic effects, including improvements in glycated blood proteins[HbA1c], fasting glucose, fasting insulin, and the homeostasis…
- Trial name
- NCT01841229
- Where
- Canada
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Insulin Resistance, Obesity
Financial Incentives to Exercise for Adolescents
Among youth populations, American Indians have the highest prevalence of diabetes in the United States. This study will use exercise as the principal lifestyle modification approach to reduce the risk of diabetes in this…
- Conditions
- Insulin Resistance, Obesity, Sedentary Lifestyle
- Trial name
- MOVE (NCT01848353)
- Testing
- Exercise training
- Where
- 2 sites in United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Diabetes, Proteinuria
The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria
Long pentraxin 3 (PTX3) is a recently discovered multimeric inflammatory mediator structurally linked to CRP and serum amyloid P-component.
- Conditions
- Diabetes, Proteinuria, Renin Angiotensin System
- Trial name
- NCT00674596
- Testing
- ramipril
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Type2 Diabetes, Diabetic Kidney Disease
Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes
Type 2 diabetes is a chronic condition whose prevalence is increasing globally. Kidney disease is a key complication of diabetes and is among the most common cause of end-stage renal disease, requiring renal replacement therapy.
- Trial name
- ACTIDIANE (NCT03184662)
- Testing
- HIPA, Counseling PA
- Where
- 20 sites in Belgium, France
- Volunteers
- 178 people
- Sponsor
- Poitiers University Hospital
Obesity & Overweight, Type 2 Diabetes
Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy.
- Conditions
- Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus
- Trial name
- NCT07641361
- Testing
- Hydration Plus, Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- State University of New York at Buffalo
Type 2 Diabetes Mellitus
Glucolipotoxicity and Type 2 Diabetes
Elevations of blood glucose and lipid are thought to be deleterious to the insulin secretory function of the pancreas. This is known as glucolipotoxicity. However, few studies have examined this in detail.
- Trial name
- NCT01375270
- Testing
- Glucotoxicity, Lipotoxicity
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diabetes Mellitus, Type 2
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time…
- Trial name
- NCT07242469
- Testing
- MK-1403 + additive coformulation
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active…
- Trial name
- SOLSTICE (NCT06579105)
- Testing
- AZD5004, Semaglutide
- Where
- 97 sites in United States, Canada and 7 more
- Volunteers
- 406 people
- Sponsor
- AstraZeneca
Obesity, Diabetes
Penn Medicine Food Market Study
The goal of this interventional study is to test ways to improve the effectiveness of a healthy foods prescription program in increasing the purchase of healthy foods for patients who have both obesity (BMI >or= 30) and diabetes…
- Trial name
- NCT06283394
- Testing
- Storefront Choice Architecture, Fresh Funds, Loss Framing
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- University of Pennsylvania
Diabetes Mellitus, Type 2
Clinical Trial on Diabetes Expert Patients Programme
The purpose of this study is to determine whether participation in a diabetes expert patients programme course is effective in self-management of a chronic condition such as diabetes, if it reduces Haemoglobin A glycosylated…
- Trial name
- EPPD-ICS (NCT01898702)
- Testing
- Diabetes expert patients programme
- Where
- 3 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Diabetes Mellitus, Type 2, Obesity
Impact of a Regional Program Agir Sur Sa SantE
The prevention and control of lifestyle-related non-communicable chronic diseases, including diabetes, obesity and cardiovascular disorders, that share common risk factors, has now become a major focus of the World Health…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Hypertension, Dyslipidemias
- Trial name
- NCT02478853
- Testing
- Implementation of a new regional care framework
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Université de Sherbrooke
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.